RxDoctor Payments Data

Stuart Fischer, MD

Cardiovascular Disease · Los Alamitos, CANPI 1083656086

Payments from drug & device makers

$112,427in general payments, 2019–2025

Across 453 payments — averaging $248.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$49K
  • CSL Behring$40K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$10K
  • AstraZeneca$7K
  • Boehringer Ingelheim$1K
  • Merck$552
  • plus $4K from 32 others

What the payments were for

  • Food & beverage$7,560100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$112,427 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$79,104
Medicare patients
161
Services billed
828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban168$193,784
XareltoRivaroxaban44$56,691
EntrestoSacubitril/Valsartan36$48,435
BrilintaTicagrelor21$24,646
VascepaIcosapent Ethyl23$15,366
Praluent PenAlirocumab23$12,745
JardianceEmpagliflozin14$11,994
FarxigaDapagliflozin Propanediol12$10,628
Repatha SureclickEvolocumab11$10,227
Icosapent Ethyl12$5,970
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,902
Flecainide Acetate36$2,803
Metoprolol Succinate158$2,152
Olmesartan Medoxomil59$1,443
Propafenone Hcl ErPropafenone Hcl15$1,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$528$193,784168 claims
Johnson & JohnsonXarelto$550$56,69144 claims
NovartisEntresto$49,416$48,43536 claims
AstraZenecaBrilinta, Farxiga$6,992$35,27433 claims
Boehringer IngelheimJardiance$1,049$11,99414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Alamitos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →